• Niagen Bioscience recently reported its strongest year to date, with 2025 net sales reaching US$129.4 million, net income of US$17.4 million, and management guiding for 2026 net sales to grow a further 10%–15% year-over-year excluding divested analytical reference standards and services revenue.
• Alongside this financial progress, the company deepened its intellectual property around nicotinamide riboside injectables and broadened into new categories such as at-home injection kits and beauty-focused supplements, reshaping how it can monetize its NAD+ science.
• Building on this expansion into injectables and beauty products, we’ll now examine how the latest results and guidance affect Niagen Bioscience’s investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Niagen Bioscience Investment Narrative Recap

To own Niagen Bioscience, you have to believe its NAD+ science and growing IP can translate into durable, profitable demand for injectables, at home kits, and beauty products. The latest results and 2026 guidance support that thesis and reinforce the near term catalyst around expanding Niagen Plus injections and e commerce, while the biggest risk remains regulatory and legal uncertainty in the NAD and NMN space, which the new information does not materially diminish.

The most closely linked announcement is management’s 2026 net sales guidance of 10 percent to 15 percent growth, driven mainly by e commerce and partnerships. This ties directly into the catalyst around higher margin direct to consumer channels and telehealth enabled injectables, but it also sets a more measured bar for how quickly newer offerings like at home injection kits and beauty supplements may contribute to overall growth.

Yet despite the strong 2025 numbers, investors should be aware that unresolved FDA and NMN issues could still...

Niagen Bioscience's narrative projects $196.4 million revenue and $33.0 million earnings by 2028. This requires 19.1% yearly revenue growth and a $15.3 million earnings increase from $17.7 million today.

Uncover how Niagen Bioscience's forecasts yield a $13.60 fair value, a 169% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$212.8 million and earnings of US$41.7 million by 2028, and they worry that slower than expected telehealth and at home kit uptake could blunt the benefit of guidance like Niagen’s new 10 percent to 15 percent 2026 sales growth range, reminding you that expectations and interpretations can differ widely and may shift again as fresh results emerge.

Explore 6 other fair value estimates on Niagen Bioscience - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Niagen Bioscience research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Niagen Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Niagen Bioscience's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.